Droperidol for treatment of nausea and vomiting in palliative care patients

Jemma Storrar; Morwenna Hitchens; Tracey Platt; Saskie Dorman

doi:10.1002/14651858.CD006938.pub3

Droperidol para el tratamiento de las náuseas y los vómitos en pacientes que reciben atención paliativa

Contraer todo Desplegar todo

Referencias

Referencias de los estudios excluidos de esta revisión

Ir a:

otras referencias
otras versiones publicadas

Aapro MS, Froidevaux P, Roth A, Alberto P. Antiemetic efficacy of droperidol or metoclopramide combined with dexamethasone and diphenhydramine. Oncology 1991;48:116-20.

Aldrete J. Reduction of nausea and vomiting from epidural opioids by adding droperidol to the infusate in home-bound patients. Journal of Pain and Symptom Management 1995;10(7):544-7.

Braude D, Soliz T, Crandall C, Hendey G, Andrews J, Weichental L. Antiemetics in the ED: a randomized controlled trial comparing 3 common agents. American Journal of Emergency Medicine 2006;24:177-82.

Casey C, Chen LM, Rabow MW. Symptom management in gynaecologic malignancies. Expert Review of Anticancer Therapy 2011;11(7):1077-89.

Cheung WY, Zimmermann C. Pharmacologic management of cancer-related pain, dyspnea and nausea. Seminars in Oncology 2011;38(3):450-9.

Dale O, Moksnes K, Kaasa S. European Palliative Care Research Collaborative Pain Guidelines: Opioid switching to improve analgesia or reduce side effects. A systematic review. Palliative Medicine 2011;25(5):494-503.

Etievant A, Betry C, Haddjeri N. Partial dopamine D2 / serotonin 5HT-1a receptor agonists as new therapeutic agents. Open Neuropsychopharmacology 2010;3:1-12.

Feyer P, Jordan K. Update and new trends in antiemetic therapy: the continuing need for novel therapies. Annals of Oncology 2011;22(1):30-8.

Fujii M, Kiura K, Kamei H, Okabe K, Toki H. Antiemetic effects of combinations of metoclopramide, dexamethasone and dexamethasone for the prevention of cisplatin-induced gastrointestinal toxicity: a randomized crossover trial [Japanese]. Gan To Kagaku Ryoho 1987;14(7):2257-61.

Getto L, Zeserson E, Breyer M. Vomiting, diarrhea, constipation and gastroenteritis. Emergency Medicine Clinics of North America 2011;29(2):211-37.

Glare P, Miller J, Nikolova T, Tickoo R. Treating nausea and vomiting in palliative care: a review. Clinical Interventions in Aging 2011;6(1):243-59.

Gonzales MJ, Widera E. Nausea and other non-pain symptoms in long-term care. Clinics in Geriatric Medicine 2011;27(2):213-28.

Hardy JR, O'Shea A, White C, Gilshenan K, Welch L, Douglas C. The efficacy of haloperidol in the management of nausea and vomiting in patients with cancer. Journal of Pain & Symptom Management 2010;40(1):111-6.

Herrstedt J, Hannibal J, Hallas J, Andersen E, Laursen LC, Hansen M. High-dose metoclopramide + lorazepam versus low-dose metoclopramide + lorazepam + dehydrobenzperidol in the treatment of cisplatin-induced nausea and vomiting. Annals of Oncology 1991;2:223-7.

Jacobs AJ, Deppe G, Cohen CJ. A comparison of the antiemetic effects of droperidol and prochlorperazine in chemotherapy with cis-platinum. Gynecologic Oncology 1980;10:55-7.

Kim H, Rosenberg SA, Steinberg SM, Cole DJ, Weber JS. A randomized double-blinded comparison of the antiemetic efficacy of ondansetron and droperidol in patients receiving high-dose interleukin-2. Journals of Immunotherapy 1994;16:60-5.

Lehoczky O, Bagameri A, Sarosi Z, Kulcsar T, Pulay T. Does the addition of an anxiolytic drug improve the antiemetic effectiveness of the steroid and granisetron combination in the prophylaxis of cisplatin-induced vomiting? [Fokozhato-e a szteroid es granisetron antiemeticus kombinacio hatekonysaga anxiolyticus szer hozzaadasaval a cisplatin okozta hanyas profilaxisaban?]. Orvosi Hetilap 2001;142:1681-4.

Lennox B, Reid M, McCaffrey D, Miaskowski C, Kaplan BH, Vogl SE. Randomized double-blind crossover trial of prochlorperazine (P) alone versus prochlorperazine plus droperidol (D) for emesis prophylaxis in patients (PTS) receiving intravenous bolus cis-platinum (DDP). Proceedings of American Association of Cancer Research 1985;26:189.

Google Scholar

Lewis GO, Bernath AM, Ellison NM, Gallagher JG, Porter PA, Rine KT. Double-blind crossover trial of droperidol, metoclopramide, and prochlorperazine as antiemetics in cisplatin therapy. Clinical Pharmacy 1984;3:618-21.

McHugh ME, Miller-Saultz D. Assessment and management of gastrointestinal symptoms in advanced illness. Primary Care - Clinics in Office Practice 2011;38(2):225-46.

McNicol A, Horowicz-Mehler N, Fisk RA, Bennett K, Gialeli-Goudas M, Chew PW, et al. Management of opioid side effects in cancer-related and chronic non-cancer pain: a systematic review. Journal of Pain 2003;4(5):231-56.

Melsom H, Nandrup E, Monge OR. Metoclopramide (Primperan) versus droperidol (Dridol) as an antiemetic in intravenous cancer chemotherapy [Metoklopramid (Primperan) versus droperidol (Dridol) som antiemetikum ved intravenos cancerkjemoterapi]. Tidsskrift for Den Norske Laegeforening 1982;102(16):914-5.

Minegishi Y, Ohmatsu H, Miyamoto T, Niho S, Goto K, Kubota K, et al. Efficacy of droperidol in the prevention of cisplatin-induced delayed emesis: a double-blind, randomised parallel study. European Journal of Cancer 2004;40:1188-92.

Muller G, Konig H. Antiemetic efficacy of high-dose metoclopramide and high-dose droperidol in preventing cisplatin-induced nausea and emesis: a single-blind comparison. Blut 1989;59(3):280.

Google Scholar

Niijima T, Isurugi K, Akaza H, Kondon Y, Kawabe K, Fujita K, et al. Randomised cross-over study on the effects of methylprednisolone, metoclopramide and droperidol on the control of nausea and vomiting associated with cis-platinum chemotherapy [Japanese]. Gan To Kagaku Ryoho 1986;13(7):2376-82.

O'Connor B, Creedon B. Pharmacological treatment of bowel obstruction in cancer patients. Expert Opinion on Pharmacotherapy 2011;12(14):2205-14.

Owens NJ, Schauer AR, Nightingale CH, Golub GR, Martin RS, Williams HM, et al. Antiemetic efficacy of prochlorperazine, haloperidol, and droperidol in cisplatin-induced emesis. Clinical Pharmacy 1984;3:167-70.

Patanwala AE, Amini R, Hays DP, Rosen P. Antiemetic therapy for nausea and vomiting in the emergency department. Journal of Emergency Medicine 2010;39(3):330-6.

Poka R, Hernadi Z, Juhasz B, Lampe L. Comparison of four antiemetic regimens for the treatment of cisplatin-induced vomiting. International Journal of Gynaecology and Obstetrics 1993;42:19-24.

Richards JR, Richards IN, Ozery G, Derlet RW. Droperidol analgesia for opioid-tolerant patients. Journal of Emergency Medicine 2011;41(4):389-96.

Roberts WS, Wisniewski BJ, Cavanagh D, Marsden DE. Droperidol as an antiemetic in cis-platinum-induced nausea and vomiting. Oncology 1985;42:42-3.

Sagae S, Ishioka S, Fukunaka N, Terasawa K, Kobayashi K, Sugmara M, et al. Combination therapy with granisetron, methylprednisolone and droperidol as an antiemetic prophylaxis in CDDP-induced delayed emesis for gynaecologic cancer. Oncology 2003;64:46-53.

Saller R, Hellenbrcht D. High doses of metoclopramide or droperidol in the prevention of cisplatin-induced emesis. European Journal of Cancer and Clinical Oncology 1986;22(10):1199-203.

Smith T, Paice J, Ritter J, Bobb B. An evidence-based approach to cutaneous treatment of nausea, pain and neuropathy in palliative care. Journal of Pain & Symptom Management 2010;39(2):372-3.

Smith T, Ritter JK, Coyne PJ, Parker GL, Dodson P, Fletcher DS. Testing the cutaneous absorption of lorazepam, diphenhydramine and haloperidol gel (ABH gel) used for cancer-related nausea. Journal of Clinical Oncology 2011;29(15 Suppl):1.

Smith T, Fletcher D, Coyne P, Ritter J, Dodson P, Parker G. ABH gel (Ativan, Benadryl, Diphenhydramine, Haloperidol, Haldol) is not absorbed from the skin of normal volunteers so cannot be effective against nausea. Journal of Pain & Symptom Management 2012;43:375-6.

Stuart-Harris R, Buckman R, Starke I, Wiltshaw E. Chlorpromazine, placebo and droperidol in the treatment of nausea and vomiting associated with cisplatin therapy. Postgraduate Medical Journal 1983;59:500-3.

Thangathurai D, Roffey P. Usefulness of droperidol as an anti-emetic in terminally ill cancer patients. Journal of Palliative Medicine 2010;13(8):939.

Tramer MR, Walder B. Efficacy and adverse effects of prophylactic antiemetics during patient-controlled analgesia therapy: a quantitative systematic review. Anesthesia and Analgesia 1999;88:1354-61.

White RM, Myers EM, Ashayeri E, Gumbs RV, Pressoir R. Induction chemotherapy for advanced head and neck cancer: modification of response to chemotherapy by antiemetics. American Journal of Clinical Oncology 1992;15(1):45-55.

Yang LPH. Abiraterone acetate: in metastatic castration-resistant prostate cancer. Drugs 2011;71(15):2067-77.

Referencias adicionales

Ir a:

estudios excluidos
otras versiones publicadas

Bentley A, Boyd K. Use of clinical pictures in the management of nausea and vomiting. Palliative Medicine 2001;15:247-53.

Carlisle J, Stevenson CA. Drugs for preventing postoperative nausea and vomiting. Cochrane Database of Systematic Reviews 2006, Issue 3. [DOI: 10.1002/14651858.CD004125.pub2]

Davis MP, Hallerberg G. A systematic review of the treatment of nausea and/or vomiting in cancer unrelated to chemotherapy or radiation. Journal of Pain and Symptom Management 2010;39(4):756-67.

Edmonds P, Karlsen S, Khan S, Addington-Hall J. A comparison of the palliative care needs of patients dying from chronic respiratory diseases and lung cancer. Palliative Medicine 2001;15:287-95.

Important drug warning. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm173778.htm 4 Dec 2001.

Glare P, Pereira G, Kristjanson L, Stockler M, Tattersall M. Systematic review of the efficacy of antiemetics in the treatment of nausea in patients with far-advanced cancer. Supportive Care in Cancer 2004;12:432-40.

Grande GE, Todd CJ. Why are trials in palliative care so difficult? Palliative Medicine 2000;14(1):69-74.

Habib AS, Gan TJ. Pro: the Food and Drug Administration black box warning on droperidol is not justified. Anesthesia and Analgesia 2008;106:1414-7.

Hadley G, Derry S, Moore RA, Wee B. Can observational studies provide a realistic alternative to randomised controlled trials in palliative care? Journal of Pain & Palliative Care Pharmacotherapy 2009;23(2):106-13.

Hirst A, Sloan R. Benzodiazepines and related drugs for insomnia in palliative care. Cochrane Database of Systematic Reviews 2001, Issue 4. [DOI: 10.1002/14651858.CD003346]

Jadad AR, Moore A, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Controlled Clinical Trials 1996;17(1):1-12.

Kao LW, Kirk MA, Evers SJ, Rosenfeld SH. Droperidol, QT prolongation, and sudden death: what is the evidence? Annals of Emergency Medicine 2003;41(4):546-8.

Klinkenberg M, Willems DL, van der Wal G, Deeg DJH. Symptom burden in the last week of life. Journal of Pain and Symptom Management 2004;27:5-13.

Ludwin DB, Shafer SL. Con: the black box warning on droperidol should not be removed (but should be clarified!). Anesthesia and Analgesia 2008;106:1418-20.

Mannix KA. Palliation of nausea and vomiting. In: Oxford Textbook of Palliative Medicine. Oxford University Press, 2004.

Martindale. The complete drug reference. www.medicinescomplete.com/mc/martindale/current 2009 (accessed 3 February 2010).

McKeage K, Simpson D, Wagstaff AJ. Intravenous droperidol: a review of its use in the management of postoperative nausea and vomiting. Drugs 2006;66(16):2123-47.

Medicines and Healthcare products Regulatory Agency. Discontinuation of Droleptan tablets, suspension and injection (droperidol). http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON019548 11 January 2001.

Medicines and Healthcare products Regulatory Agency. Marketing authorisations granted in January 2008. http://www.mhra.gov.uk/home/groups/l-reg/documents/licensing/con014139.pdf.

Nuttall GA, Eckerman KM, Jacob KA, Pawlaski EM, Wigersma SK, Shirk Marienau ME, et al. Does low-dose droperidol administration increase the risk of drug-induced QT prolongation and Torsade de Pointes in the general surgical population? Anesthesiology 2007;107:531-6.

Perkins P, Dorman S. Haloperidol for the treatment of nausea and vomiting in palliative care patients. Cochrane Database of Systematic Reviews 2009, Issue 2. [DOI: 10.1002/14651858.CD006271.pub2]

Rhodes VA, McDaniel RW. Nausea, vomiting and retching: complex problems in palliative care. CA: A Cancer Journal for Clinicians 2001;51:232-48.

Twycross R, Back I. Nausea and vomiting in advanced cancer. European Journal of Palliative Care 1998;5:39-45.

Google Scholar

Wee B, Hadley G, Derry S. How useful are systematic reviews for informing palliative care practice? Survey of 25 Cochrane systematic reviews. BMC Palliative Care 2008;7:13.

Referencias de otras versiones publicadas de esta revisión

Ir a:

estudios excluidos
otras referencias

Dorman S, Perkins P. Droperidol for treatment of nausea and vomiting in palliative care patients. Cochrane Database of Systematic Reviews 2010, Issue 10. [DOI: 10.1002/14651858.CD006938.pub2]

Characteristics of studies

Characteristics of excluded studies [ordered by study ID]

Study	Reason for exclusion
Aapro 1991	Population not restricted to adults receiving palliative care or suffering from an incurable progressive medical condition. Underlying diagnoses not clear. Prophylaxis of chemotherapy‐associated nausea and vomiting
Aldrete 1995	Population not restricted to adults suffering from an incurable progressive medical condition
Braude 2006	Population not restricted to adults receiving palliative care or suffering from an incurable progressive medical condition. Any diagnosis causing nausea or vomiting
Casey 2011	Not a RCT; not specific to droperidol
Cheung 2011	Not specific to droperidol
Dale 2011	Not a RCT; not specific to droperidol
Etievant 2010	Not specific to droperidol, nausea or vomiting
Feyer 2011	Prophylaxis and treatment of chemotherapy‐induced nausea and vomiting
Fujii 1987	Prophylaxis of chemotherapy‐associated nausea and vomiting
Getto 2011	Population not restricted to adults receiving palliative care or suffering from an incurable progressive medical condition
Glare 2011	Not specific to droperidol
Gonzales 2011	Not specific to droperidol
Hardy 2010	Not specific to droperidol
Herrstedt 1991	Population not restricted to adults receiving palliative care or suffering from an incurable progressive medical condition. Prophylaxis of chemotherapy‐associated nausea and vomiting
Jacobs 1980	Population not restricted to adults receiving palliative care or suffering from an incurable progressive medical condition (stage of cancers not documented). Prophylaxis of chemotherapy‐associated nausea and vomiting
Kim 1994	Prophylaxis of interleukin‐associated nausea and vomiting
Lehoczky 2001	Not randomised. Prophylaxis of chemotherapy‐associated nausea and vomiting
Lennox 1985	Population not restricted to adults receiving palliative care or suffering from an incurable progressive medical condition. Prophylaxis of chemotherapy‐associated nausea and vomiting. Abstract only
Lewis 1984	Population not restricted to adults receiving palliative care or suffering from an incurable progressive medical condition. Prophylaxis of chemotherapy‐associated nausea and vomiting
McHugh 2011	Not specific to droperidol
McNicol 2003	Systematic review rather than randomised controlled trial. Not specific to droperidol, nausea or vomiting
Melsom 1982	Prophylaxis of chemotherapy‐associated nausea and vomiting
Minegishi 2003	Population not restricted to adults receiving palliative care or suffering from an incurable progressive medical condition (stage of cancers not documented). Prophylaxis of chemotherapy‐associated nausea and vomiting
Muller 1989	Inadequate detail to assess population (abstract only), but not restricted to adults receiving palliative care or suffering from an incurable progressive medical condition. Prophylaxis of chemotherapy‐associated nausea and vomiting
Niijima 1986	Population not restricted to adults receiving palliative care or suffering from an incurable progressive medical condition. Prophylaxis of chemotherapy‐associated nausea and vomiting
O'Connor 2011	Not specific to droperidol
Owens 1984	Population not restricted to adults receiving palliative care or suffering from an incurable progressive medical condition. Prophylaxis of chemotherapy‐associated nausea and vomiting
Patanwala 2010	Not randomised. Population not restricted to adults receiving palliative care or suffering from an incurable progressive medical condition
Poka 1993	Population not restricted to adults receiving palliative care or suffering from an incurable progressive medical condition. Prophylaxis of chemotherapy‐associated nausea and vomiting
Richards 2011	Not specific to droperidol, nausea or vomiting
Roberts 1985	Population not restricted to adults receiving palliative care or suffering from an incurable progressive medical condition. Prophylaxis of chemotherapy‐associated nausea and vomiting
Sagae 2003	Population not restricted to adults receiving palliative care or suffering from an incurable progressive medical condition. Prophylaxis of chemotherapy‐associated nausea and vomiting
Saller 1986	Population not restricted to adults receiving palliative care or suffering from an incurable progressive medical condition. Prophylaxis of chemotherapy‐associated nausea and vomiting
Smith 2010	Not specific to droperidol
Smith 2011	Not specific to droperidol
Smith 2012	Not specific to droperidol
Stuart‐Harris 1983	Population not restricted to adults receiving palliative care or suffering from an incurable progressive medical condition. Prophylaxis of chemotherapy‐associated nausea and vomiting
Thangathurai 2010	Not a RCT
Tramer 1999	Population not restricted to adults receiving palliative care or suffering from an incurable progressive medical condition. Prophylaxis of postoperative nausea and vomiting
White 1992	Not a RCT ‐ groups treated sequentially. Prophylaxis of chemotherapy‐associated nausea and vomiting
Yang 2011	Not specific to droperidol, nausea or vomiting

RCT: randomised controlled trial

Figure 1

Study flow diagram.

Ir a la figura de la revisiónAbrir en una pestaña nueva

	Idioma de la Revisión Cochrane Escoja su idioma de preferencia para las revisiones Cochrane y otros contenidos. Las secciones sin una traducción aparecerán en inglés.

	Idioma de la web Escoja su idioma de preferencia para la web de la Biblioteca Cochrane.

Idioma de la Revisión Cochrane

Idioma de la web

Referencias

Referencias de los estudios excluidos de esta revisión

Aapro 1991 {published data only}

Aldrete 1995 {published data only}

Braude 2006 {published data only}

Casey 2011 {published data only}

Cheung 2011 {published data only}

Dale 2011 {published data only}

Etievant 2010 {published data only}

Feyer 2011 {published data only}

Fujii 1987 {published data only}

Getto 2011 {published data only}

Glare 2011 {published data only}

Gonzales 2011 {published data only}

Hardy 2010 {published data only}

Herrstedt 1991 {published data only}

Jacobs 1980 {published data only}

Kim 1994 {published data only}

Lehoczky 2001 {published data only}

Lennox 1985 {published data only}

Lewis 1984 {published data only}

McHugh 2011 {published data only}

McNicol 2003 {published data only}

Melsom 1982 {published data only}

Minegishi 2003 {published data only}

Muller 1989 {published data only}

Niijima 1986 {published data only}

O'Connor 2011 {published data only}

Owens 1984 {published data only}

Patanwala 2010 {published data only}

Poka 1993 {published data only}

Richards 2011 {published data only}

Roberts 1985 {published data only}

Sagae 2003 {published data only}

Saller 1986 {published data only}

Smith 2010 {published data only}

Smith 2011 {published data only}

Smith 2012 {published data only}

Stuart‐Harris 1983 {published data only}

Thangathurai 2010 {published data only}

Tramer 1999 {published data only}

White 1992 {published data only}

Yang 2011 {published data only}

Referencias adicionales

Bentley 2001

Carlisle 2006

Davis 2010

Edmonds 2001

Food and Drug Administration 2001

Glare 2004

Grande 2000

Habib 2008

Hadley 2009

Hirst 2001

Jadad 1996

Kao 2003

Klinkenberg 2004

Ludwin 2008

Mannix 2004

Martindale 2009

McKeage 2006

MHRA 2001

MHRA 2008

Nuttall 2007

Perkins 2009

Rhodes 2001

Twycross 1998

Wee 2008

Referencias de otras versiones publicadas de esta revisión

Dorman 2010

Characteristics of studies

Characteristics of excluded studies [ordered by study ID]

Copiar o descargar referencia

Idioma de la Revisión Cochrane

Idioma de la web

Instituciones a las que se accedió previamente

Usuarios institucionales

Instituciones a las que se accedió previamente